mAbxience and Abiogen Pharma Announce Strategic Licensing Agreement for Biosimilar Candidate in Italy

On May 26, 2025 mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Abiogen Pharma reported a new strategic licensing agreement to develop and commercialize a biosimilar candidate in Italy (Press release, mAbxience, MAY 26, 2025, View Source [SID1234653380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of this agreement, mAbxience will hold the marketing authorization for the biosimilar candidate, while Abiogen Pharma will be responsible for all commercialization and marketing activities in Italy. This collaboration combines mAbxience’s expertise in biosimilar development with Abiogen Pharma’s strong presence and commercial capabilities in the Italian market.

"We are thrilled to partner with Abiogen Pharma to bring this biosimilar candidate to patients in Italy. Our collaboration reflects mAbxience’s commitment to delivering high-quality, accessible therapies across various geographies," said José Ramón Millán, Global Partnering & Portfolio Director at mAbxience.

"This agreement is part of a broader, long-term strategic path for us," said Prisca Di Martino, Chief Commercial Officer at Abiogen Pharma. "It reflects our dedication to therapeutic areas where we bring deep expertise. Partnering with mAbxience supports our goal to expand access to advanced biologic therapies in Italy. This is another step towards innovative, sustainable solutions for patients and healthcare systems."

This agreement marks another milestone in mAbxience’s strategy to provide affordable, life-saving therapies worldwide. Both mAbxience and Abiogen Pharma expect that this partnership will enhance patient access to advanced treatments, while also helping healthcare systems manage the rising costs of biologic therapies.